Tag Archive for: Tissue Tech

Former Chief Scientific and Medical Officer Advanced Wound Care, Smith & Nephew

Life Science Partner recruited Bert Slade, MD, to serve as the Vice President, Clinical Development for TissueTech.  Slade has built his career in leading clinical trials, medical affairs, and regulatory approvals for medical device and pharmaceutical companies worldwide.  He joins TissueTech while also providing clinical support for Chisholm Clinical Research Services where he has set up his own vehicle to conduct clinical trials using the European platform as an inroad to EU product approvals.

During his tenure at Smith and Nephew, Slade was challenged as the first CMO for the Advanced Wound Management Division to restructure the three-strategic business unit R&D Departments and two clinical groups into a single international R&D organization with the addition of post-marketing surveillance.

“With his extensive experience in FDA submissions of BLAs and NDAs including a clinical background in wound healing and regenerative medicine, Slade will serve as a critical asset for TissueTech’s clinical trial designs and submissions,” states Tom Callaway, President and Founding Partner of Life Science Partner.

Slade earned his Bachelor of Arts Degree in Biology from Hamilton College.  He earned his MD from the Upstate Medical Center at the University of New York.

Former Medical Director, Global Medical Marketing, ConvaTec

Life Science Partner recruited Michel Hermans, MD, a surgically trained medical affairs executive to become Chief Medical Officer for TissueTech.

Hermans joins TissueTech after serving as a biopharma consultant for his own firm and Medical Director, Global Medical Marketing for ConvaTech.   Previously, Hermans served served as Medical Director for Ortec where he successfully led the new clinical trials for the commercialization of OrCel globally.

TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, orthopedic reconstructive surgeries and wound care markets.

TissueTech offers its portfolio products through its commercial entities: BioTissue, Inc., the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, and Amniox Medical, a leading technology provider to the orthopedic and wound care markets.

“Hermans has the direct clinical trials management experience that leads to the approval of biologics in the BLA regulatory pathway – and brings that background to TissueTech’s clinical and regulatory strategy,” states Tom Callaway, MD, Founder and President of Life Science Partner.  “In addition, as a specialist in treating burn patients, he brings real-life clinical experience to the company.”

Hermans earned his Medical Degree from the University of Groningen in the Netherlands and completed his training in general surgery, burn and trauma care from the Rode Kruis Ziekenhuis and Burn Center in Beverwijk, Netherlands.